Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback